Bimatoprost with timolol
Brand names: Ganfort
This is a fixed-combination eye drop of bimatoprost, a prostaglandin analogue, with timolol, a non-selective beta-blocker, used to lower intraocular pressure in open-angle glaucoma and ocular hypertension when a single agent is insufficient.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Bimatoprost increases uveoscleral outflow of aqueous humour while timolol reduces aqueous production by the ciliary epithelium; the two complementary actions give greater pressure reduction than either alone.
Prescribing in practice
- Because of the timolol component, avoid in patients with asthma, a history of bronchospasm, severe COPD, sinus bradycardia, heart block or uncontrolled heart failure, and warn about systemic beta-blockade.
- Bimatoprost can cause permanent darkening and lengthening of eyelashes and iris hyperpigmentation, especially in mixed-colour irides.
- Advise punctal occlusion or eyelid closure after instillation to reduce systemic absorption, and remove contact lenses before use.
Monitoring
Monitor intraocular pressure and, in at-risk patients, heart rate and respiratory status, with periodic assessment for periocular pigmentary and lash changes.
Counselling the patient
- Instil once daily, usually in the evening, and press gently on the inner corner of the eye for a short while afterwards.
- Iris and eyelid skin may darken and lashes may grow longer and thicker, sometimes permanently.
- Tell your clinician about any breathing problems, wheeze or a slow heartbeat.
Evidence & guidelines
NICE glaucoma guidance supports fixed-combination prostaglandin/beta-blocker drops to improve adherence when monotherapy fails to control intraocular pressure adequately.
Reference: NICE NG81; RCOphth; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- C-Peptide to Glucose Ratio · Diabetes Classification
- International Staging System (ISS) for Multiple Myeloma · Multiple Myeloma
- Revised ISS (R-ISS) for Multiple Myeloma · Haematological Malignancy
- International Staging System for Multiple Myeloma (ISS) · Oncology
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme